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Poster Session II S257Background: Palifermin at 60ug/kg/dose, decreases the severity of
oral mucositis (OM) in adults with hematologic malignancies
undergoing SCT. Currently there is no proven therapy to decrease
severe OM in pediatric subjects receiving chemotherapy +/- radia-
tion for SCT. Reducing severe OM in pediatrics should decrease
infection, pain, and enteral nutrition use and improve outcome
following SCT.
Study Design: Phase 1 dose escalation study of palifermin to deter-
mine the safety and dosing for pediatric subjects with acute leuke-
mia’s undergoing myeloablative allogeneic SCT.
Conditioning regimen: Palifermin SCT Days -10 to -8 and 0 to
+2, 1200 cGy (200 cGy  6 fractions) TBI, etoposide 1500 mg/m2,
and cyclophosphamide 120 mg/kg.
24 patients have been enrolled. Three age groups studied: 1 to 2, 3
to 11, and 12 to 16 years old. Three dose levels studied: 40, 60, and
80ug/kg/day. All groups have completed enrollment except 1 to 2
year group at 80ug/kg/dose.
Results: Safety data-no deaths, dose limiting toxicities (DLT), or
treatment related serious adverse events (SAE’s). The most common
adverse event related to palifermin was rash, 6/24 subjects (4/6 in the
80, and 1/9 in the 60 and 40 ug/kg/dose groups), followed by puritis,
3/24 subjects (2/6 in the 80 and 1/9 in the 60 ug/kg/dose group).
Pharmacokinetic data was not sufficient to show if linear pharma-
cokinetics occurs or if age impacts the pharmacokinetics in pediat-
rics. No accumulation of palifermin after 3 consecutive daily doses
occurred. Antibodies to palifermin were not seen on blood samples
obtained on SCT day -10, +30 and +100. OM grades 3 and 4 were
seen in 3/9 subjects receiving 40, 5/9 receiving 60, and 0/6 receiving
80 ug/kg/dose. 6/24 subjects had . grade 2 graft versus host
disease.
Conclusion: 1. No DLT’s and no SAE’S in any of the completed
age/dose groups. The 1 to 2 year group continues to enroll at 80
ug/kg/dose with no DLT’s or SAE’’s in the 40 and 60 ug/kg/dose
levels.
2. No grade 3/4 OM occurred in the 80 ug/kg/dose, suggesting
a relationship between palifermin dosing and severity of OM.
3. The data review team recommended a palifermin dose of 80 ug/
kg/dose for 3 to 11 and 12 to 16 year old age groups for future effi-
cacy studies. The incidence of OM was less and no SAE’s at this dose,
however the number of patients this is based on is small.
4. Recommendations for future efficacy studies for the 1 to 2 age
group will be made when the 80 ug/kg dose is completed.269
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Mucosal barrier injury caused by HSCT chemoradiotherapy
conditioning leads to translocation of bacteria and bacterial prod-
ucts, including LPS-bearing bacteria and free LPS, into the sys-
temic circulation. LPS signaling through its TLR4 receptor
results in inflammatory cytokine release and resulting hypotension,
fever, coagulopathy and end organ dysfunction. In allogeneic mu-
rine HSCT models, prior immunization to LPS, blockade of
LPS:TLR4 signaling and use of LPS hyporesponsive mice all de-
crease HSCT morbidity and mortality, particularly acute GVHD
and interstitial pneumonia. As humans are both very LPS sensitive
and known to be endotoxemic early peri-HSCT, we initiated
a cohort dose escalation Phase I/II study of rBPI21, a recombinant
fragment of a neutrophil granule cationic protein with potent LPS-
neutralizing activity in vivo, in patients (pts) undergoing conven-
tional allogeneic myeloablative HSCT with sibling or unrelatedPBSC or BM. The first cohort (CHT1) filled with 6 pts aged
17-65 (median 54 yrs). Pts received 4 mg/kg bolus IV rBPI21 Day
(D) -1 followed by 6 mg/kg/D continuous IV for 3 D. No severe
adverse events (AE) were seen. A prospective observational
HSCT study (OBS) enrolled 13 pts aged 35-59 (median 48) meet-
ing trial eligibility who gave blood samples on the same schedule.
All CHT1 AE through discharge were # Grade (Gr) 3. 10 Gr 3
AEs were seen: mucositis (3), infections (ID,5), and hypertension
(2). In OBS, pts had 23 Gr 3, 7 Gr 4 and 3 Gr 5 AE – Gr 3: mu-
cositis (7), ID (10), hyper/hypotension (2), liver (3), renal (1); Gr
4:cardiac (3), mucositis (2), liver (1), ID (1); Gr 5: 1 each VOD,
ARDS, DAH. Time to engraftment was the same. LPS, by endo-
toxin activity assay (EAA, Spectral Diagnostics), and cytokine levels
were drawn before conditioning, D -1 (pre rBPI21), D0, D2 (end of
rBPI21) and weekly to D21. CHT1 EAA levels were\OBS at all
timepoints, p \ .033 at D2. IL6 levels, reflective of bioactive
LPS, increased less from baseline in CHT1 at all timepoints vs
OBS, p\ .014 D 14. Other assays are in process. The trial closed
after CHT1 due to rBPI21 supply issues. However, this first human
trial of LPS neutralization during HSCT supports feasibility and
tolerability. There is encouraging evidence of bioactivity, and pos-
sible decreased HSCT morbidity, at a biologically suboptimal dose.
Additional studies with this or similar LPS antagonists should be
performed to fully evaluate potential efficacy in attenuating
HSCT toxicity including GVHD.270
CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE IN HEMATAPOETIC
STEM CELL TRANSPLANTATION RECIPIENTS
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Clostridium Difficile-associated disease(CDAD) is a source of
morbidity and mortality for hematapoetic stem cell transplantation
recipients(HSCT). Risk factors for the development of CDAD are
largely unknown. We retrospectively reviewed 822 HSCT recipient
charts for the incidence of CDAD and evaluated risk factors and out-
comes associated with CDAD.
Methods: 822 consecutive HSCT recipients(615 autologous/207 al-
logeneic) from Northwestern Memorial Hospital (NMH)between
2004-08 were reviewed. CDAD was evaluated from the day of admis-
sion until dischage following HSCT. All patients received acyclovir,
ciprofloxacin and an azole as prophylaxis. Cefepime(CEF) or Piper-
acillin/Tazobactam(P/T) were initiated for neutropenic(NTP) fe-
ver. Due to NMH policy changes, 50% of patients received a low
microbial diet, while 50% did not. Bivariate analysis was used to eval-
uate the correlation between CDAD and dependent variables. This
study was approved by NMH IRB.
Results: Results for 83 patients identified with CDAD are listed in
table 1.There was a significant difference in the incidence of
CDAD between autologous and allogeneic HSCT 14.5% vs
8.5%: p5 .023)respectively. There was no association between
CDAD and age, sex, diagnosis, or conditioning regimen(except
more CDAD patients received RIST:p5 .027). Median time to oc-
currence of CDAD was 8days post-HSCT. Time to engraftment
was similar for CDAD and non-CDAD HSCT recipients(12 and
11 days respectively). A significant correlation was found between
patients who were colonized with VRE and subsequent develop-
ment of CDAD(p5 .0014). Patients who were fed a low microbial
diet(auto/allo matched) were also at increased risk for CDAD (51/
411 vs 32/411:p5 .05). Neither CEF nor P/T treatment was asso-
ciated with CDAD. Vancomycin use was associated with increased
risk for CDAD although patients were initiated only 1 day(median)
prior to CDAD. No correlation was found between patients who
developed NTP fever during HSCT and CDAD and the number
of co-infections was similar in CDAD and non-CDAD patients.
11/30 allo HSCT recipients who had CDAD developed Grade 3-
4 GI GVH within 30d of CDAD treatment. Overall inpatient mor-
tality was significantly greater for patients with CDAD(7/82 vs 25/
740: p5 .032)
Conclusion: CDAD poses a risk for increased morbidity and mor-
tality for recipients of HSCT. Identification and correction of
